Results 251 to 260 of about 1,406,780 (315)

Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors. [PDF]

Br J Haematol
Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Buganè A, Pellegrini C, Broccoli A, Zinzani PL.   +9 more
europepmc   +1 more source

Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California. [PDF]

Open Forum Infect Dis
Katrak SS, Wang RC, Keh CE, Nabity SA, Okada RC, Raftery A, Wendorf KA, Agraz-Lara R, Chakrabarty M, Chevinsky JR, Chitnis AS, Dasgupta-Tsinikas S, Goozé L, Kadakia A, Kaiser C, Louie JK, Morgan J, Nguyen TD, Percak J, Polesky AH, Radner A, Sahni H, Sreenivasan M, Sherrick R, Soukup JD, Waterman C, Yeturu P, Yu S, Barry PM.   +28 more
europepmc   +1 more source

Comprehensive characterization of the inflammatory ecosystems in immunotherapy-induced adverse events versus chronic inflammatory diseases. [PDF]

J Immunother Cancer
Kang J, An J, Choi JK.
europepmc   +1 more source

Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ahuja A, Prasad S, Manoharan S, Sen A, Rana R, Mody M, Paras F, Archita A, Shaik S, Mehta K, Manoj R, Mishra P, Mehta S, Kapoor P.   +13 more
europepmc   +1 more source

Adverse events in both childhood and adulthood are associated with molecular, clinical and functional markers of ageing. [PDF]

BMC Med
Aas M, Hoppen TH, Morina N, Zhang S, Li B, Mlakar V, Mutz J.   +6 more
europepmc   +1 more source